MDxHealth is trading 9.44% down now at $0.19 after suspending 2026 revenue guidance following preliminary third-quarter revenue of approximately $22.7 million, below expectations.
- The company attributed disruption to unexpected sales-force turnover following the discontinuation of Resolve mdx.
- On October 19, BTIG downgraded the stock to Neutral from Buy, citing the revenue miss and guidance suspension.